---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-039304"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:55:05.944011+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion reports Q4 2023 net loss $34.9M; cash $177.2M; clinical data readouts expected 2024

## Summary
- Net loss $117.3M for FY 2023 vs $81.8M in 2022; Q4 loss $34.9M vs $25.3M.
- Cash, equivalents, restricted cash, investments $177.2M at Dec 31, 2023, up from $113.4M year earlier.
- R&D expenses $102.5M for FY 2023, up from $62.7M, driven by BMF-219 and BMF-500 clinical costs.
- Phase 2 type 2 diabetes data showed continued glycemic control 5 months off therapy; expansion cohort of 216 patients underway.
- Phase 2 type 1 diabetes study (COVALENT-112) initiated; initial data readout anticipated in 2024.

## SEC filing metadata
- accession: 0000950170-24-039304
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000095017024039304/0000950170-24-039304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000095017024039304/bmea-20240401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-039304
- JSON: https://secwatch.observer/filing/0000950170-24-039304.json
- Plain text: https://secwatch.observer/filing/0000950170-24-039304.txt

## Key facts
- Earnings Releases
  Biomea Fusion, Inc. reported financial results for fourth quarter and full year 2023.
  - Period: fourth quarter and full year 2023
  - Result: reported results
  source text: Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840439/000095017024039304/0000950170-24-039304-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.